£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Cathal Friel, chairman and co-founder of Poolbeg Pharma. What keeps him going is ‘the fun and enjoyment of creating companies’
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
hVIVO PLC (AIM:HVO) Imutex Phase I data published
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
hVIVO PLC (AIM:HVO) £13.6m RSV human challenge study contract with biopharma client
Study cohort sizes increase as clients recognise the benefits of human challenge
Open Orphan PLC (AIM:ORPH) Change of name to hVIVO plc effective
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
Open Orphan PLC (AIM:ORPH) CFO appointment & change of Board roles
Open Orphan plc (Ticker: ORPH), (to be renamed hVIVO plc (Ticker: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan PLC (AIM:ORPH) Positive in vitro results for FLU-v published in Vaccines
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan PLC (AIM:ORPH) CEO share purchase
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan plc (AIM:ORPH) Upcoming Scientific Presentations
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious
Open Orphan PLC (AIM:ORPH) Press Speculation
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the media
Open Orphan PLC (AIM:ORPH) Interim results and Trading Update
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing